NEW YORK (Reuters) - Bristol-Myers Squibb Co <BMY.N> set a better-than-expected baseline for profits in 2013 as it provided investors their first glimpse of life after Plavix, the second-largest selling drug in the world. Bristol on Thursday projected 2013 earnings, excluding items, of at least $1.95 per share. That would appear to be a potential decline of ...

CHANGING OF THE GUARD: Jim Cornelius, CEO of drugmaker Bristol-Myers Squibb Co., is retiring May 4, to be succeeded by Chief Operating Officer Lamberto Andreotti. STRATEGY IMPACT: Andreotti, a key architect of the drugmaker's plan to shed noncore businesses and buy biotech products and companies, intends ...

Drugmaker Bristol-Myers Squibb Co. said Tuesday its chief executive will retire in May and be succeeded by the current chief operating officer. The move is the fourth official retirement from a senior health company executive position for James M. Cornelius, who had run Bristol-Myers for ...

Federal health advisers said Monday an organ transplant drug from Bristol-Myers Squibb Co. should be approved for patients receiving a new kidney, despite mixed results when compared with older drugs. The Food and Drug Administration drug advisory panel voted 13-5 in favor of the company's drug belatacept to prevent organ rejection in patients implanted with a new kidney. FDA ...